Clinical breast examination (CBE) is superior to MRI for predicting pathologic complete response (pCR) in women with HER2-positive breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium indicates.
A new tool may show promise for improving clinical trial participation among black women with breast cancer, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Research presented at SABCS 2016 identified biomarkers predictive of response to trastuzumab-containing therapies in patients with HER2-positive breast cancer.
Results of a comparison study of radioactive seed localization and wire guided localization in patients with nonpalpable invasive breast cancer or DCIS were presented at SABCS 2016.
Patients with HER2-positive, HR-positive advanced breast cancer experience significantly improved progression-free survival when pertuzumab is added to first-line trastuzumab and an AI compared with trastuzumab and an AI alone, according to study findings presented at SABCS 2016.
A novel bromodomain-containing protein 4 inhibitor demonstrated antitumor activity in both endocrine-sensitive and endocrine-resistance breast cancer models, according to a study presented at SABCS 2016.
Investigators report on the efficacy of a structured prophylactic regimen of loperamide for 2 cycles to reduce incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer, at SABCS 2016.
In this presentation at SABCS 2016, researchers present an evaluation of the ability of the PAM50 HER2-enriched intrinsic subtype to predict pathologic complete response in the breast in patients who received 18 weeks of neoadjuvant dual HER2 blockade.
Researchers found that temporary pretreatment with LDA may protect normal breast tissue during chemotherapy for breast cancer in patients undergoing breast-conserving therapy, according to a study presented at SABCS 2016.
In a poster presentation at SABCS 2016, researchers reported on the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of CINV in patients receiving highly or moderately emetogenic chemotherapy.
